Circulating MicroRNA-122 for the Diagnosis of Hepatocellular Carcinoma: A Meta-Analysis
Joint Authors
Lin, Dong-Dong
Zhao, Xiao-Fei
Li, Ning
Sun, Li-Bo
Source
Issue
Vol. 2020, Issue 2020 (31 Dec. 2020), pp.1-10, 10 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2020-03-27
Country of Publication
Egypt
No. of Pages
10
Main Subjects
Abstract EN
Background.
Circulating microRNA-122 (miR-122) has been recognized as a marker of hepatocellular carcinoma (HCC).
The current meta-analysis was performed to quantitatively evaluate the diagnostic performance of circulating miR-122 for HCC.
Methods.
Related studies that evaluated the diagnostic performance of circulating miR-122 determined from pathophysiological examination for HCC were obtained by systematic searches of the PubMed and Embase databases.
A randomized fixed effects model was applied according to the heterogeneity among studies.
The pooled sensitivity, specificity, and area under the summary receiver operating characteristic curve (AUC) were calculated to evaluate the diagnostic accuracy.
Publication bias was detected by Deeks’ funnel plot asymmetry test.
Results.
Thirteen studies providing data for 920 HCC patients and 1217 controls were included in the meta-analysis.
The pooled sensitivities, specificities, and AUCs of serum miR-122 were 0.76, 0.75, and 0.82, respectively, for discriminating HCC patients from overall controls; 0.85, 0.83, and 0.91, respectively, for discriminating HCC patients from healthy controls; 0.79, 0.82, and 0.87, respectively, for discriminating HCC from HBV or HCV infection; and 0.65, 0.75, and 0.74, respectively, for discriminating HCC from liver cirrhosis or dysplastic nodule formation.
No significant publication bias was detected.
Conclusions.
Serum miR-122 confers moderate efficacy for discriminating HCC patients from healthy controls or patients with HBV or HCV infection, but not for discriminating HCC patients from those with liver cirrhosis or dysplastic nodule formation.
American Psychological Association (APA)
Zhao, Xiao-Fei& Li, Ning& Lin, Dong-Dong& Sun, Li-Bo. 2020. Circulating MicroRNA-122 for the Diagnosis of Hepatocellular Carcinoma: A Meta-Analysis. BioMed Research International،Vol. 2020, no. 2020, pp.1-10.
https://search.emarefa.net/detail/BIM-1134716
Modern Language Association (MLA)
Zhao, Xiao-Fei…[et al.]. Circulating MicroRNA-122 for the Diagnosis of Hepatocellular Carcinoma: A Meta-Analysis. BioMed Research International No. 2020 (2020), pp.1-10.
https://search.emarefa.net/detail/BIM-1134716
American Medical Association (AMA)
Zhao, Xiao-Fei& Li, Ning& Lin, Dong-Dong& Sun, Li-Bo. Circulating MicroRNA-122 for the Diagnosis of Hepatocellular Carcinoma: A Meta-Analysis. BioMed Research International. 2020. Vol. 2020, no. 2020, pp.1-10.
https://search.emarefa.net/detail/BIM-1134716
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1134716